Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

15 Oct 2022

Abstract excerpt

Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36243743
DOI: 10.1038/s41541-022-00543-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccinesPMID 36243743Read ↗

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine PlatformSemantic proximity Read ↗

Understanding the Measles Virus at 70 Years: From Cellular Mechanisms to Immunisation, 1954-2024Semantic proximity Read ↗

The use of viral vectors in vaccine developmentSemantic proximity Read ↗

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read ↗

Viral vectors for vaccine applicationsSemantic proximity Read ↗

A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 VaccineSemantic proximity Read ↗

Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In VivoSemantic proximity Read ↗

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationSemantic proximity Read ↗

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventionsSemantic proximity Read ↗

A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoVSemantic proximity Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.